04/2017
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640
AACR Annual Meeting
Read More
02/2017
Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target
Pharmacology and Therapeutics
Read More
12/2016
Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel
San Antonio Breast Cancer Symposium
Read More
12/2016
FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression
EBioMedicine
Read More
11/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640
NCRI Cancer Conference
Read More
09/2016
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients
Precison: Lung Cancer R&D Summit
Read More
08/2016
DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics
Journal of Cell Signaling
Read More
06/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
ASCO Annual Meeting
Read More
04/2016
FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study
AACR Annual Meeting
Read More
04/2016
Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640
AACR Annual Meeting
Read More